Literature DB >> 27664396

[18F]JNJ42259152 binding to phosphodiesterase 10A, a key regulator of medium spiny neuron excitability, is altered in the presence of cyclic AMP.

Maarten Ooms1, Bala Attili1, Sofie Celen1, Michel Koole2, Alfons Verbruggen1, Koen Van Laere2, Guy Bormans1.   

Abstract

Phosphodiesterase 10A (PDE10A) is a key regulator of medium spiny neuron excitability. Therefore, it plays an important role in the regulation of motor, reward, and cognitive processes. Despite the interest in PDE10A as a drug and positron emission tomography (PET) imaging target, little is known about the regulation of PDE10A enzymatic activity. This study aimed to further investigate the role of cAMP in the regulation of PDE10A activity and PDE10A PET imaging. Using [18 F]JNJ42259152 as radioligand, we investigated alterations in PDE10A binding secondary to changes in cAMP levels. An in vitro striatum homogenate binding assay was developed to determine KD and Bmax of [18 F]JNJ42259152. Homogenate binding was assessed after addition of increasing concentrations of exogenous cAMP (1, 10, and 100 μM). Rats were treated using JNJ49137530 and rolipram to induce in vivo alterations of cAMP. The effect of the induced cAMP alterations on PDE10A binding was assessed by comparing [18 F]JNJ42259152 microPET studies after treatment to microPET studies acquired at baseline conditions prior to treatment. In vitro binding affinity of [18 F]JNJ42259152 was higher in the presence of cAMP compared to baseline conditions (KD  = 3.17 ± 0.91 nM with 10 μM cAMP vs. KD  = 6.62 ± 0.7 nM at baseline). Inhibition of PDE4 using rolipram significantly increased [18 F]JNJ42259152 binding (BPND  = 2.61 ± 0.50 vs. 1.91 ± 0.36 at baseline). Administration of the PDE2 inhibitor JNJ49137530 significantly increased PDE10A binding potential (BPND  = 2.74 ± 0.22 vs. 2.05 ± 0.16 at baseline). Our data indicate an important role for cAMP in the regulation of PDE10A activity. Additionally, our data show a profound interaction between several PDEs in striatum.
© 2016 International Society for Neurochemistry.

Entities:  

Keywords:  [18F]JNJ42259152; brain imaging; cyclic AMP; phosphodiesterase 10A; small animal PET

Mesh:

Substances:

Year:  2016        PMID: 27664396     DOI: 10.1111/jnc.13855

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  5 in total

1.  In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Authors:  Hui Liu; Hongjun Jin; Zonghua Luo; Xuyi Yue; Xiang Zhang; Hubert Flores; Yi Su; Joel S Perlmutter; Zhude Tu
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

2.  Imaging phosphodiesterase-10a availability in cocaine use disorder with [11 C]IMA107 and PET.

Authors:  Savannah Tollefson; Joshua Gertler; Michael L Himes; Jennifer Paris; Steve Kendro; Brian Lopresti; N Scott Mason; Rajesh Narendran
Journal:  Synapse       Date:  2018-09-27       Impact factor: 2.562

Review 3.  Challenges on Cyclic Nucleotide Phosphodiesterases Imaging with Positron Emission Tomography: Novel Radioligands and (Pre-)Clinical Insights since 2016.

Authors:  Susann Schröder; Matthias Scheunemann; Barbara Wenzel; Peter Brust
Journal:  Int J Mol Sci       Date:  2021-04-07       Impact factor: 5.923

4.  Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats.

Authors:  Bart de Laat; Yvonne E Kling; Gwen Schroyen; Maarten Ooms; Jacob M Hooker; Guy Bormans; Koen Van Laere; Jenny Ceccarini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-17       Impact factor: 9.236

Review 5.  Pyrazoles as Key Scaffolds for the Development of Fluorine-18-Labeled Radiotracers for Positron Emission Tomography (PET).

Authors:  Pedro M O Gomes; Artur M S Silva; Vera L M Silva
Journal:  Molecules       Date:  2020-04-09       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.